You just read:

Polaryx Therapeutics Submits Investigational New Drug Application to the U.S. FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis With PLX-200

News provided by

Polaryx Therapeutics, Inc

Dec 23, 2019, 00:00 ET